Update on the Cediranib and Sunitinib Clinical Trials for Alveolar Soft Part Sarcoma Phase II in the USA

  Please note the two Phase II clinical trials available for ASPS patients in the US:

1.   Sunitinib or Cediranib for Alveolar Soft Part Sarcoma, study number NCT01391962

Contact: NCI Referral Office, Tel.   1-888-NCI-1937

Locations:

United States, California
Santa Monica Oncology Center
Santa Monica, California, United States, 90403

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892

United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115

United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030-4096

2.   Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma, study number NCT00942877

Contact:

Agnes T. Strassberger, R.N.    Tel.  (301) 435-5664,   e-mail:  agnes.strassberger@nih.gov

Location:

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892

______________________________________________________

Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)
e-mail:
landesmany@yahoo.com